Combined analysis of EGF+61G>A and TGFB1+869T>C functional polymorphisms in the time to androgen independence and prostate cancer susceptibility

Pharmacogenomics Journal

Volumn 9, Issue 5, 2009, Pages 341-346

  Teixeira, A L ^a,b   Ribeiro, R ^a,b   Morais, A ^a   Lobo, F ^a   Fraga, A ^a   Pina, F ^c   Calais da Silva, F M ^d   Calais da Silva, F E ^d   Medeiros, R ^a,b  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c Hospital Militar do Porto   (Portugal)

^d Lisbon Regional Blood Centre   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; ANTIANDROGEN; CYTOSINE; EPIDERMAL GROWTH FACTOR; GONADORELIN AGONIST; GUANINE; THYMINE; TRANSFORMING GROWTH FACTOR BETA1;

AGED; AMINO ACID SUBSTITUTION; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER HORMONE THERAPY; CANCER RISK; CANCER SUSCEPTIBILITY; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; FOLLOW UP; GENETIC ANALYSIS; GENETIC PREDISPOSITION; GENOTYPE; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENOMICS; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ANDROGENS; CASE-CONTROL STUDIES; CELL PROLIFERATION; EPIDERMAL GROWTH FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; ODDS RATIO; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RISK ASSESSMENT; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 70349694553     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2009.20     Document Type: Article

References (50)

1. Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosc 2006; 11: 1388-1413.
2. Pronzato P, Rondini M. Hormonotherapy of advanced prostate cancer. Ann Oncol 2005; 4: Iv80-iv84.
3. Hellerstedt B, Pienta K. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 2002; 52: 154-179.
4. Catalona WJ. Management of cancer of the prostate. N Engl J Med 1994; 331: 996-1003.
5. Martín-Orozco R, Almaroz-Pro C, Rodríguez-Ubreva FJ, Cortés MA, Ropero S, Colomer R et al. EGF prevents the neuroendocrine differentiation of LNCaP Cells induced by serum deprivation: The modulator role of PI3K/Akt. Neoplasia 2007; 9: 614-624.
6. Long R, Morrissey C, Fitzpatrick J. Prostate epithelial cell differentiation and its relevance to the understanding of prostate cancer therapies. Clin Sci 2005; 108: 1-11.
7. Fisher DA, Lakshmanan J. Metabolism and effects of epidermal growth factor and related growth factors in mammals. Endocr Rev 1990; 11: 418-442.
8. Groenen LC, Nice EC, Burgess AW. Structure-function relationships for the EGF/TGF- family of mitogens. Growth Factors 1994; 11: 235-257.
9. Vicentini C, Festuccia C, Gravina GL, Angelucci A, Marronaro A, Bologna M. Prostate cancer cell proliferation is strongly reduced by epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines primary cultures. J Cancer Res Clin Oncol 2003; 129: 165-175.
10. Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002; 8: 3438-3444.
11. Shahbazi M, Pravica V, Nasreen N, Fakhoury H, Fryer AA, Strange RC et al. Association between functional polymorphism in EGF gene and malignant melanoma. Lancet 2002; 359: 397-401.
12. Bhowmick D, Zhuang Z, Wait SD, Weil RJ. A functional polymorphism in the EGF gene is found with increased frequency in glioblastoma multiforme patients and is associated with more aggressive disease. Cancer Res 2004; 64: 1220-1223.
13. Costa B, Ferreira P, Costa P, Canedo P, Oliveira P, Silva A et al. Association between functional EGF+61 polymorphism and glioma risk. Clin Cancer Res 2007; 13: 2621-2625.
14. MacCarron S, Bateman A, Theaker J, Howell WM. EGF+61 gene polymorphism and susceptibility to and prognostic markers in cutaneous malignant melanoma. Int J Cancer 2003; 107: 673-675.
15. Ribeiro R, Soares A, Pinto D, Catarino R, Lopes C, Medeiros R. EGF genetic polymorphism is associated with clinical features but not malignant phenotype in neurofibromatosis type 1 patients. J Neurooncol 2007; 81: 225-229.
16. Teixeira AL, Ribeiro R, Cardoso D, Pinto D, Lobo F, Fraga A et al. Genetic Polymorphism in EGF is associated with prostate cancer agressiveness and progression-free-interval in androgen blockade-treated patients. Clin Cancer Res 2008; 14: 3367-3371.
17. Elliott R, Blobe G. Role of transforming growth factor beta in human cancer. J Clin Oncol 2005; 23: 2078-2093.
18. Reiss M, Barcellos-Hoft MH. Transforming growth factor-b in breast cancer: A working hypothesis. Breast Cancer Res Treat 1997; 45 81-95.
19. Kretzschmar M. Transforming growth factor-b and breast cancer. Transforming growth factor-b/SMAD signaling effects and cancer. Breast Cancer Res 2000; 2: 107-115.
20. Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, Metcalfe JC et al. Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet 1999; 8 93-97.
21. Yokota M, Ichihara S, Lin TL, Nakashima N, Yamada Y. Association of a T29C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation 2000; 101: 2783-2787.
22. Soulitzis N, Karyotis I, Delakas D, Spandidos DA. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia. Int J Oncol 2006; 29 305-314.
23. Jakowlew S. Transforming growth factor-β in cancer and metastasis. Cancer Metastatis Rev 2006; 25: 435-457.
24. Gudmundsson J, Sulem P, Steinthorsdottir V, Bergthorsson JT, Thorleifsson G, Manolescu A et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet 2007; 39: 977-983.
25. Zheng SL, Sun J, Wiklund F, Smith S, Stattin P, Li G et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med 2008; 358: 910-919.
26. Haiman CA, Patterson N, Freedman ML, Myers SR, Pike MC, Waliszewska A et al. Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet 2007; 39: 638-644.
27. Glinsky GV. Phenotype-defining functions of multiple non-coding pathway. Cell Cycle 2008; 7: 1630-1639.
28. Glinsky GV. An SNP-guided microRNA map of fifteen common human disorders identifies a consensus disease phenocode aiming at principal components of the nuclear import pathway. Cell Cycle 2008; 7: 2570-2583.
29. Gregory H, Willshire IR, Kavanagh JP, Blacklock NJ, Chowdury S, Richards RC. Urogastrone-epidermal growth factor concentrations in prostatic fluid of normal individuals and patients with benign prostatic hypertrophy. Clin Sci (Lond) 1986; 70: 359-363.
30. Harper ME, Glynne-Jones E, Goddard L, Mathews P, Nicholson RI. Expression of androgen receptor and growth factors in premalignant lesions of the prostate. J Pathol 1998; 186: 169-177.
31. Stearns ME, Garcia FU, Fudge K, Rhim J, Wang M. Role of interleukin 10 and transforming growth factor b1 in the angiogenesis and metastasis of human prostate primary tumor lines from orthotopic implants in severe combined immunodeficiency mice. Clin Cancer Res 1999; 5: 711-720.
32. Kaklamani V, Pasche B. the role of TGF-β in cancer and the potential for therapy and prevention. Expert Rev Anticancer Ther 2004; 4 649-661.
33. Tang B, de Castro K, Barnes HE, Parks WT, Stewart L, Böttinger EP et al. Loss of responsiveness of to transforming growth factor beta induces malignant transformation of nontumorigenic rat prostate epithelial cells. Cancer Res 1999; 59: 4834-4842.
34. Bierie B, Moses H. TGF-β: The molecular jekyll and Hyde of cancer. Nat Rev 2006; 6: 506-520.
35. Zhou W, Park I, Pins M, Kozlowski JM, Jovanovic B, Zhang J et al. Dual regulation of proliferation and growth arrest in prostatic stromal cells by transforming growth factor-β1. Endocrinology 2003; 144: 4280-4284.
36. Paterson IC, Davies M, Stone A, Huntley S, Smith E, Pring M et al. TGF-b1 acts as a tumor suppressor of human malignant keratinocytes independently of Smad 4 expression and ligand-induced G1 arrest. Oncogene 2002; 21: 1616-1624.
37. Bierie B, Moses HL. TGF-beta and cancer. Cytokine Growth Factor Rev 2006; 17: 29-40.
38. Guo Y, Kyprianou N. Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis. Cancer Res 1999; 59: 1366-1371.
39. Medeiros R, Vasconcelos A, Costa S, Pinto D, Ferreira P, Lobo F et al Metabolic susceptibility genes and prostate cancer risk in a southern European population: The role of glutathione S-transferases GSTM1, GSTM3, And GSTT1 genetic polymorphisms. Prostate 2004; 58: 414-420.
40. Medeiros R, Morais A, Vasconcelos A, Costa S, Pinto D, Oliveira J et al. The role of vitamin D receptor gene polymorphisms in the susceptibility to prostate cancer of a southern European population. J Hum Genet 2002; 47: 413-418.
41. Ribeiro R, Vasconcelos A, Costa S, Pinto D, Morais A, Oliveira J et al. Overexpressing leptin genetic polymorphism (-2548G/A) is associated with susceptibility to prostate cancer and risk of advanced disease. Prostate 2004; 59: 268-274.
42. Zheng SL, Sun J, Wiklund F, Smith S, Stattin P, Li G et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med 2008; 358: 910-919.
43. Dunning AM, Ellis PD, McBride S, Kirschenlohr HL, Healey CS, Kemp PR et al. A transforming growth factor b1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res 2003; 63: 2610-2615.
44. Bonaccorsi L, Carloni V, Muratori M, Formigli L, Zecchi S, Forti G et al. EGF receptor (EGFR) signalling promoting invasion is disrupted in androgen-sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR). Int J Cancer 2004; 112: 78-86.
45. Angelucci A, Schenone S, Gravina G, Muzi P, Festuccia C, Vicentini C et al. Pyrazolo [3,4-d] pyrimidines c-Src inhibitors reduce epidermal growth factor-induced migration in prostate cancer cells. Eur J Cancer 2006; 42: 2838-2845.
46. Taille A, Vacherot F, Salomon L, Druel C, Gil Diez De Medina S, Abbou C et al. Hormone-refractory prostate cancer: A multi-step and multi-event process. Prostate Cancer Prostatic Dis 2001; 4: 204-212.
47. Zhu M-L, Partin JV, Bruckheimer EM, Strup SE, Kyprianou N. TGF-b signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells. Prostate 2008; 68: 287-295.
48. Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl 1989; 2: 33-50.
49. Fortunel NO, Hatzfeld A, Hatzfeld JA. Transforming growth factor-beta: pleiotropic role in the regulation of hematopoiesis. Blood 2000; 96: 2022-2036.
50. Mullenbach R, Lagoda PJ, Welter C. An efficient salt-chloroform extraction of DNA from blood and tissues. Trends Genet 1989; 5 391.